Atria Investments Inc Reduces Holdings in Johnson & Johnson $JNJ

Atria Investments Inc lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 238,582 shares of the company’s stock after selling 4,444 shares during the quarter. Atria Investments Inc’s holdings in Johnson & Johnson were worth $36,443,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Greenup Street Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 3.1% in the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock worth $309,000 after buying an additional 60 shares during the period. Ellis Investment Partners LLC increased its stake in Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after purchasing an additional 62 shares during the period. Cypress Wealth Services LLC boosted its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after purchasing an additional 62 shares during the period. Horizon Bancorp Inc. IN increased its stake in Johnson & Johnson by 11.2% in the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after buying an additional 64 shares during the period. Finally, Global Strategic Investment Solutions LLC lifted its holdings in Johnson & Johnson by 3.5% during the 2nd quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock valued at $294,000 after buying an additional 65 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Stifel Nicolaus increased their price target on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. The Goldman Sachs Group lifted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Citigroup upped their price objective on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Finally, UBS Group raised their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Trading Down 0.3%

Johnson & Johnson stock opened at $186.39 on Thursday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The stock has a market cap of $449.07 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50-day moving average of $182.88 and a two-hundred day moving average of $167.17.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.